Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073870 | 0.84 | GPR119 (0.46) | GPR119KMT2AALDH1A1CYP1A2 | |
| SCHEMBL87245 | 0.82 | POLB (0.42) | GPR119KMT2ALMNAMAPK1ALDH1A1 | |
| SCHEMBL11956438 | 0.80 | GPR119 (0.43) | GPR119ALDH1A1CYP1A2TSHR | |
| SCHEMBL17307166 | 0.79 | GPR119 (0.36) | GPR119 | |
| SCHEMBL6460378 | 0.79 | TLR4 (0.35) | LMNAMAPK1ALDH1A1 | |
| SCHEMBL9895084 | 0.79 | TLR4 (0.35) | LMNAMAPK1ALDH1A1 | |
| SCHEMBL2212358 | 0.78 | GPR119 (0.35) | GPR119 | |
| SCHEMBL12401055 | 0.78 | GPR119 (0.35) | GPR119LMNAMAPK1 | |
| SCHEMBL102412 | 0.78 | GPR119 (0.38) | GPR119LMNAMAPK1 | |
| SCHEMBL1192952 | 0.78 | GPR119 (0.35) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383637-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-02-26 | — | — | US | claimed |
| EP-1776349-B1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-06 | — | — | EP | claimed |
| EP-1776349-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | claimed |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | US | claimed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | claimed |
| CN-108504364-A | Liquid crystal composition | 株式会社东进世美肯 | 2018-09-07 | — | — | CN | disclosed |
| EP-2909181-B1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9394257-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| EP-1776349-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | disclosed |
| EP-1776350-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | US | disclosed |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2006-04-13 | — | — | US | disclosed |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
| WO-2006024932-A1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006017844-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | GPR119 11/4885KMT2A 963/4885LMNA 4185/4885 |
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | GPR119 2308/4885KMT2A 2035/4885LMNA 2653/4885 |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | GPR119 2308/4885KMT2A 2035/4885LMNA 2653/4885 |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | GPR119 2308/4885KMT2A 2035/4885LMNA 2653/4885 |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | GPR119 52/4885KMT2A 454/4885LMNA 1822/4885 |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | GPR119 52/4885KMT2A 454/4885LMNA 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.